SCHEMBL16341884

SCHEMBL16341884

COC(=O)c1cc(Cl)nc2[nH]nc(I)c12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
NQO2 P16083 10/20 0.41
ABL1 P00519 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 3/20 0.37
KMT2A Q03164 2/20 0.37
F2 P00734 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29904835 0.87 ALDH1A1 (0.41) KDM4ESMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL14759956 0.87 ALDH1A1 (0.41) KDM4ESMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL14769541 0.85 AHR (0.35) KDM4ESMN1; SMN2KMT2AGAAMEN1
SCHEMBL14816677 0.84 KDM4E (0.47) KDM4ENQO2ABL1SMN1; SMN2ALDH1A1
SCHEMBL16476633 0.84 KDM4E (0.33) KDM4ESMN1; SMN2ALDH1A1MAPTMAPK1
SCHEMBL16476635 0.80 KDM4E (0.43) KDM4ENQO2ABL1SMN1; SMN2ALDH1A1
SCHEMBL31347233 0.77 KDM4E (0.46) KDM4ENQO2ABL1SMN1; SMN2ALDH1A1
SCHEMBL26104506 0.77 KDM4E (0.46) KDM4ENQO2ABL1SMN1; SMN2ALDH1A1
SCHEMBL25211367 0.74 KDM4E (0.43) KDM4EALDH1A1MAPK1GAATSHR
SCHEMBL30989273 0.74 KDM4E (0.43) KDM4EALDH1A1MAPK1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846712-B2 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors SANOFI (FR) 2014-09-30 US disclosed
EP-2567959-B1 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2014-04-16 EP disclosed
US-20130065894-A1 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065894-A1 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS MAP3K1, MAP4K2, MAP3K6 KDM4E 1053/4885NQO2 673/4885ABL1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.